UNSPSC 51111785: Pertuzumab

Pertuzumab is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer.

UNSPSC 51111785 Pertuzumab is a Commodity code representing a monoclonal antibody therapeutic indicated for HER2-positive cancers; state and local governments rarely procure this code directly as a standalone pharmaceutical, and the recent opportunities tagged under it reflect a fundamental mismatch between the code's nominal scope and actual buying patterns. Of the eight most recent opportunities flagged under this code, only two tangentially involve pharmaceutical procurement at all. Dane County's RFP for pharmaceutical services to Badger Prairie Health Care Center (due October 22, 2026) seeks a long-term care facility pharmacy contractor to manage drug and supply distribution, medication dispensing with barcode scanning, and integration with electronic patient care systems—a services contract for full-spectrum pharmacy operations rather than a purchase of Pertuzumab or any specific drug product. West Texas Centers for Mental Health and Mental Retardation's RFX for prescription and pharmacy services (proposals due August 21, 2026) similarly solicits a pharmacy services provider for over 7,000 individuals across 35 sites rather than procurement of a branded therapeutic. The City of Tucson Fire Department's RFP for BLS/ALS pharmaceuticals and supplies (due June 24, 2026) and Seminole County's IFB for Naloxone and drug deactivation systems (due July 26, 2023) represent emergency medical supply procurement, not oncology therapeutics. Remaining opportunities—a Notice of Intent to Single Source a mobile app for EMS protocol integration (Collier County), a networking event (Marion County Reverse Trade Show), a grant application process (Bernalillo County opioid settlement funding), and a forensic drug standards procurement (Pinellas County)—fall entirely outside pharmaceutical product procurement.

State and local procurement activity under this code does not support a viable business development strategy targeting Pertuzumab or related therapeutic sales. The code appears to be incorrectly applied to these opportunities, or the taxonomy does not align with how state and local healthcare entities structure purchases of specialty pharmaceuticals. Issuing bodies managing pharmaceutical procurement typically use broader services-level codes for pharmacy operations contracts or negotiate through group purchasing organizations rather than issuing direct product RFPs for branded therapeutics. Geographic activity shown spans Florida, Wisconsin, Texas, Oregon, Colorado, California, and Arizona, but no jurisdiction is targeting Pertuzumab procurement specifically. Given the complete absence of relevant recent opportunities, this code warrants skip status unless business development can confirm that state or local health plans, hospital systems, or medicaid agencies in target markets are considering standalone specialty pharmaceutical purchasing vehicles.